Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy by Taiwo, B. et al.
Associations of T cell activation and inflammatory biomarkers with
virological response to darunavir/ritonavir plus raltegravir therapy
Babafemi Taiwo1*, Roy M. Matining2, Lu Zheng2, Michael M. Lederman3, Charles R. Rinaldo4, Peter S. Kim5,
Baiba I. Berzins1, Daniel R. Kuritzkes6, Amy Jennings7, Joseph J. Eron Jr8 and Cara C. Wilson9
1Division of Infectious Diseases, Northwestern University, Chicago, IL 60611, USA; 2Statistical Data Analysis Center, Harvard School of
Public Health, Boston, MA 02115, USA; 3Department of Medicine, Case Western Reserve University, University Hospitals/Case Medical
Center, Cleveland, OH 44106, USA; 4Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15261,
USA; 5Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-7628,
USA; 6Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA; 7Frontier
Science & Technology Research Foundation, Inc. Amherst, NY, USA; 8Division of Infectious Diseases, University of North Carolina at
Chapel Hill, Chapel Hill, NC 27514, USA; 9Division of Infectious Diseases, University of Colorado, Denver, CO 80262, USA
*Corresponding author. Tel: +1-312-695-5085; Fax: +1-312-695-5088; E-mail: b-taiwo@northwestern.edu
Received 28 January 2013; returned 21 February 2013; revised 5 March 2013; accepted 10 March 2013
Objectives: One of the goals of antiretroviral therapy (ART) is to attenuate HIV-induced systemic immune
activation and inflammation. We determined the dynamics of biomarkers of immune activation, microbial
translocation and inflammation during initial ART with a nucleos(t)ide-sparing regimen of darunavir/ritonavir
plus raltegravir. We also evaluated associations between these biomarkers and the virological response to
the regimen.
Methods: We determined baseline and week 24 and 48 levels of CD4+ and CD8+ T cell activation (% HLA-DR+/
CD38+), interleukin-6 (IL-6), interferon-g-inducible protein-10 (IP-10), soluble CD14 (sCD14), D-dimer and lipo-
polysaccharide. Associations between the biomarkers at baseline were assessed using Spearman’s rank correl-
ation. The Wilcoxon signed rank test analysed changes from baseline. Comparisons between groups were made
using the Wilcoxon rank sum test, and Cox proportional hazards models assessed predictors of virological
failure (VF).
Results: Assays were completed on 107 of 112 subjects after excluding five subjects who had only baseline
samples. The subjects included were 94 (88%) men with a median age of 37 years, a median baseline CD4
count of 261.5 cells/mm3 and a median baseline viral load (VL) of 75 876 copies/mL. Subjects with a baseline
VL .100000 copies/mL had higher baseline T cell activation, IL-6, IP-10, sCD14 and D-dimer. These biomarkers
declined during treatment (P,0.05). Although subjects who experienced VF had higher baseline CD4+ T cell
activation (P¼0.035), only baseline VL independently predicted VF (hazard ratio for .100000 versus
≤100000 copies/mL was 4.5–5.6, P≤0.002).
Conclusions: Darunavir/ritonavir plus raltegravir attenuated immune activation, inflammation and microbial
translocation. T cell activation remained higher in subjects with VF than those without. Baseline VL
.100000 copies/mL remained the primary driver of VF.
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Introduction
In the ACTG A5262 trial, treatment-naive HIV-1-infected patients
received a nucleos(t)ide-sparing regimen of 800/100 mg of
darunavir/ritonavir once daily plus 400 mg of raltegravir twice
daily for 52 weeks.1 This regimen was effective in most patients,
but 26% experienced protocol-defined virological failure (VF)
by week 48, approximately two-thirds of whom had a viral
load (VL) between 50 and 200 copies/mL at VF. Baseline VL
.100000 copies/mL strongly predicted VF.
One of the goals of antiretroviral therapy (ART) is to attenuate
the systemic immune activation and inflammation induced by
HIV.2 Whether these factors and microbial translocation inde-
pendently influence virological outcomes has not been clearly
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demonstrated. We investigated the dynamics of biomarkers of
immune activation, microbial translocation and inflammation
in the A5262 trial and explored the relationships between
these biomarkers and VF.
Materials and methods
Peripheral blood mononuclear cells were isolated by density centrifuga-
tion from whole blood samples collected pre-entry and at weeks 0
(entry), 24 and 48 of therapy. Samples were cryopreserved and analysed
in batches at the end of the study. T cell activation (percentage of CD4+
and CD8+ T cells coexpressing HLA-DR and CD38) was measured by flow
cytometry.3 To assay soluble biomarkers of immune activation and
inflammation, frozen plasma in EDTA anticoagulant or frozen serum
was thawed once and analysed in batch. Interleukin-6 (IL-6),
interferon-g-inducible protein-10 (IP-10) and soluble CD14 (sCD14)
were measured in plasma by ELISA (R&D Systems, Minneapolis, MN,
USA). D-dimers were measured using the Asserachrom D-DI immuno-
assay (Diagnostica Stago, Asnieres, France). For measurement of bacter-
ial lipopolysaccharide (LPS), serum was diluted to 10% or 20% with
endotoxin-free water and then heated at 858C for 15 min to denature
the proteins. LPS levels were then quantified using a modified Limulus
Amebocyte Lysate (LAL) assay (Lonza, Walkersville, MD, USA).
Baseline was defined as the average of the pre-entry and entry values
except for LPS, for which the baseline was the value obtained at entry (in
a confirmed fasting state). Associations between biomarkers at baseline
were assessed using Spearman’s rank correlation. The Wilcoxon signed
rank test analysed changes from baseline; comparisons between
groups were made using the Wilcoxon rank sum test, and Cox proportion-
al hazards models assessed predictors of VF. Tests were performed using
a 5% level of significance with no adjustment for multiple testing. Ethics
committees at each research site approved the study. Each participant
provided written informed consent.
Results
Biomarker levels at baseline
Assays were completed on 107 of 112 subjects after excluding five
subjects who had only baseline samples. The subjects included
were 94 (88%) men with a median age of 37 years, a median base-
line CD4 count of 261.5 cells/mm3 and a median baseline VL of
75 876 copies/mL. At baseline, median (IQR) CD4+ Tcell activation
was 11% (7%–20%) while median CD8+ Tcell activation was 39%
(29%–51%). Median values for IL-6, LPS, IP-10, sCD14
and D-dimer were 1.38 pg/mL (0.81–2.37 pg/mL), 21 pg/mL
(10–35 pg/mL), 517 pg/mL (349–929 pg/mL), 2.42×106 pg/mL
(1.96–3.08×106 pg/mL) and 202 ng/mL (111–362 ng/mL),
respectively. Patients with baseline VL .100000 copies/mL had
higher baseline CD4+ and CD8+ T cell activation as well as
higher IL-6, IP-10, sCD14 and D-dimer levels than those with VL
≤100000 copies/mL (all P≤0.035). Only LPS levels did not differ
between the two baseline strata of VL (P¼0.90) (Table 1).
The baseline log10 VL correlated inversely with the baseline
CD4+ T cell count (r¼20.44) and directly with CD4+ T cell acti-
vation (r¼0.39), CD8+ T cell activation (r¼0.28), IL-6 (r¼0.31),
IP-10 (r¼0.43) and sCD14 (r¼0.33) (all P≤0.003). A weaker
direct correlation was present with D-dimers (r¼0.19, P¼0.05)
and none with LPS (r¼0.01, P¼0.95).
Changes in the levels of biomarkers during treatment
Among the entire study population, all assessed biomarkers
except LPS declined significantly from baseline to weeks 24
and 48 (Table 1). Median LPS levels at entry (21 pg/mL) and at
weeks 24 (26 pg/mL) and 48 (22 pg/mL) were not significantly
different (all P.0.1).
The group with a baseline VL .100000 copies/mL experi-
enced a greater decrease in CD4+ T cell activation from baseline
to week 24 (28% versus 24%, P¼0.017) and week 48 (211%
versus 25%, P¼0.006) than did the group with a baseline VL
≤100000 copies/mL. Despite the greater decline, CD4+ T cell ac-
tivation remained higher in those with a baseline VL
.100000 copies/mL at week 24 (8% versus 5%, P,0.001) and
week 48 (5% versus 3%, P¼0.003). CD8+ T cell activation was
also higher in the high VL group at weeks 24 (18% versus 11%,
P¼0.007) and 48 (11% versus 9%, P¼0.031), although we did
not detect a significant difference between the two groups in
the decline in CD8+ T cell activation from baseline to weeks 24
(P¼0.374) and 48 (P¼0.084). Patients with a baseline VL
.100000 copies/mL had greater falls in most assessed
markers on treatment, but absolute levels of IL-6, LPS, IP-10,
sCD14 and D-dimer at weeks 24 and 48 were similar in the
two baseline VL groups.
Associations between VF and levels of assessed
biomarkers
In univariate analysis, baseline CD4+ T cell activation was higher
among patients who subsequently experienced VF than among
those who did not (median 16% versus 10%, P¼0.035). Baseline
CD8+ T cell activation, IL-6, LPS, IP-10, sCD14 and D-dimers
showed no association with subsequent VF (all P≥0.086).
During treatment, there was a consistent pattern in which the
group with VF had higher T cell activation than the group
without VF. This was observed for CD4+ T cell activation at
week 24 (8% in those with VF versus 5% without VF, P¼0.001)
and week 48 (6% versus 3%, respectively; P¼0.006); and also
for CD8+ T cell activation at weeks 24 (21% versus 12%, respect-
ively; P¼0.015) and 48 (17% versus 10%, respectively;
P¼0.010). In contrast, we did not detect a significant association
between any of the other assessed biomarkers and VF, except
for higher D-dimer levels at week 24 among those with VF
(177 versus 119 ng/mL, P¼0.025).
We next compared the change in assessed biomarkers from
baseline to weeks 24 and 48 in patients with and without VF. For
CD4+ T cell activation, no significant difference was observed
between the two groups (all P.0.05), while for CD8+ Tcell activa-
tion, the decline in CD8+ T cell activation from baseline was less in
patients with VF (P¼0.005 at week 24, P¼0.008 at week 48). No
significant difference was detected in the change from baseline
to weeks 24 and 48 for IL-6, LPS, IP-10, sCD14 or D-dimer in
patients with VF versus those without VF (all P≥0.057).
Because a high proportion of patients showing treatment
failure in the A5262 trial had a VL of 51–200 copies/mL at VF,
we conducted a subgroup analysis comparing those with a VL
≤200 copies/mL with those with a VL .200 copies/mL at VF
(n¼17 versus n¼10, respectively). In this subgroup analysis,
those with VL ≤200 copies/mL at VF had a higher baseline CD8+
T cell activation (44% versus 23%, P¼0.039). No difference was
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detected in baseline CD4+ T cell activation or in IL-6, LPS, IP-10,
sCD14 and D-dimer levels between these subgroups (all
P≥0.115). CD4+ and CD8+ T cell activation at weeks 24 and 48
was similar in the two groups, as were all other assessed
markers except sCD14, which at week 48 showed a higher concen-
tration in the ≤200 copies/mL failure group (2.44×106 versus
1.73×106 pg/mL, P¼0.027).
Finally, multivariable Cox PH regression models for time to VF
evaluating baseline VL and individual baseline biomarkers (CD4+
T cell activation, CD8+ T cell activation, IL-6, LPS, IP-10, sCD14 or
D-dimer) showed that baseline VL .100000 copies/mL was in-
dependently predictive of VF (hazard ratio for .100000 versus
≤100000 copies/mL was 4.5–5.6, P≤0.002) No independent as-
sociation was detected between the risk of VF and baseline levels
Table 1. Immunological and inflammatory markers [median (IQR)] by baseline HIV-1 RNA
Marker Totala
Baseline HIV-1 RNA (copies/mL)
≤100000b .100000c P value*
CD4+/HLA-DR+/CD38+ % baseline 11 (7, 20) 9 (5, 15) 18 (9, 23) ,0.001
week 24 5 (3, 9) 5 (2, 6) 8 (5, 12) ,0.001
week 24 D 26 (211, 22)# 24 (29, 22)# 28 (213, 23)# 0.017
week 48 3 (2, 7) 3 (2, 5) 5 (3, 8) 0.003
week 48 D 27 (214, 24)# 25 (211, 23)# 211 (216, 25)# 0.006
CD8+/HLA-DR+/CD38+ % baseline 39 (29, 51) 36 (26, 50) 46 (33, 55) 0.014
week 24 16 (9, 23) 11 (8, 19) 18 (10, 27) 0.007
week 24 D 222 (232, 213)# 220 (230, 213)# 225 (234, 214)# 0.374
week 48 10 (7, 16) 9 (6, 13) 11 (9, 21) 0.031
week 48 D 227 (237, 216)# 224 (233, 216)# 230 (239, 220)# 0.084
IL-6 (pg/mL) baseline 1.38 (0.81, 2.37) 1.11 (0.70, 2.01) 1.73 (1.25, 3.15) 0.003
week 24 1.17 (0.65, 1.76) 1.06 (0.65, 1.67) 1.19 (0.66, 1.91) 0.848
week 24 D 20.32 (20.97, 0.18)# 20.14 (20.71, 0.28)# 20.61 (22.08, 20.02)# 0.040
week 48 1.17 (0.63, 1.66) 1.13 (0.53, 1.66) 1.21 (0.65, 1.69) 0.526
week 48 D 20.37 (20.96, 0.22)# 20.22 (20.69, 0.26)# 20.42 (21.64, 0.12)# 0.299
LPS (pg/mL) baseline 21 (10, 35) 21 (10, 33) 20 (10, 38) 0.899
week 24 26 (12, 35) 26 (10, 35) 25 (12, 36) 0.800
week 24 D 0 (29, 12) 1 (28, 13) 0 (210, 10) 0.557
week 48 22 (6, 34) 16 (5, 34) 25 (12, 33) 0.478
week 48 D 21 (212, 8) 23 (214, 5) 4 (211, 12) 0.176
IP-10 (pg/mL) baseline 517 (349, 929) 425 (282, 673) 690 (459, 1184) ,0.001
week 24 180 (140, 326) 175 (136, 332) 194 (144, 280) 0.642
week 24 D 2296 (2555, 2144)# 2185 (2395, 298)# 2481 (2968, 2260)# ,0.001
week 48 172 (123, 249) 173 (122, 267) 166 (123, 246) 0.737
week 48 D 2344 (2649, 2141)# 2255 (2447, 275)# 2522 (2999, 2304)# ,0.001
sCD14 (×106 pg/mL) baseline 2.42 (1.96, 3.08) 2.11 (1.71, 2.90) 2.75 (2.16, 3.16) 0.002
week 24 2.03 (1.63, 2.37) 2.02 (1.57, 2.28) 2.06 (1.69, 2.63) 0.377
week 24 D 20.46 (20.97, 0.08)# 20.21 (20.93, 0.12)# 20.71 (21.09, 20.25)# 0.046
week 48 1.98 (1.65, 2.43) 2.00 (1.62, 2.41) 1.95 (1.68, 2.56) 0.815
week 48 D 20.41 (21.01, 0.06)# 20.22 (20.70, 0.12)# 20.71 (21.24, 20.07)# 0.021
D-dimer (ng/mL) baseline 202 (111, 362) 160 (105, 332) 266 (140, 513) 0.035
week 24 136 (73, 258) 118 (70, 255) 147 (82, 260) 0.331
week 24 D 245 (2130, 212)# 234 (2113, 22)# 264 (2170, 225)# 0.036
week 48 130 (78, 251) 144 (85, 255) 129 (74, 232) 0.566
week 48 D 262 (2148, 212)# 247 (2100, 11)# 283 (2212, 239)# 0.013
aDepending on assay result availability, n ranges from 96 to 107.
bDepending on assay result availability, n ranges from 52 to 59.
cDepending on assay result availability, n ranges from 44 to 48.
*Exact Wilcoxon rank sum test comparing baseline HIV-1 RNA ≤100000 and .100000 copies/mL.




of T cell activation, or with any of the soluble markers when
baseline VL was included in the model.
Discussion
In this study, evaluated biomarkers of immune activation, in-
flammation and microbial translocation were, except for LPS,
higher at baseline in patients with VL .100000 copies/mL. Dar-
unavir/ritonavir plus raltegravir was associated with a significant
decline from baseline in biomarkers (IL-6, sCD14 and D-dimer)
that are predictive of mortality.4 – 6 We did not observe a
change in LPS with treatment, but are unable to dissect this
finding from potential confounders. The median baseline LPS in
our study was 21 pg/mL, 4-fold lower than that reported in
other studies.7,8 This could have limited the sensitivity of the
assay to discriminate differences at low levels.
As a group, patients with VF had consistently higher T cell
activation during treatment compared with those without VF, sug-
gesting that the magnitude of T cell activation during treatment
reflects HIV levels, similar to observations for untreated infection.9
Only baseline VL .100000 copies/mL remained independently pre-
dictive of VF after considering T cell activation or soluble inflamma-
tory biomarkers. T cell activation levels were not significantly
different between those with VL ≤200 versus .200 copies/mL at
VF, although this analysis was limited by the small sample size.
The persistence of heightened activation during ART has been
reported even in some patients with VL under 50 copies/mL,10,11es-
pecially those with poor CD4 recovery.12
In conclusion, darunavir/ritonavir plus raltegravir attenuated
immune activation, inflammation and microbial translocation.
T cell activation remained higher in patients with VF than
in those without VF. Baseline VL above 100000 copies/mL
remained the primary driver of VF with this regimen even when
accounting for baseline biomarker levels. Larger studies compar-
ing this novel regimen to conventional nucleos(t)ide-containing
therapy should further elucidate the potential interactions
between T cell activation and VF.
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